Arcadia Biosciences, Inc.
About Arcadia Biosciences, Inc.
Arcadia Biosciences Inc is a company with science-based approaches to develop high value products and drive innovation in the consumer goods industry. The company has one operating and reportable segment, which derives revenue from the sale of Zola coconut water. The company's consumer brands in the food, beverage, and body care categories, and others. Its products include: Zola Coconut Water, and Agronomic Wheat Traits. Geographically, the company operates in United States, Argentina, India, and Canada. It derives maximum revenue from United States.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $4.9M
- Net income
- -$2.3M
- Total assets
- $6.5M
- Market cap
- $2.2M
- Gross margin
- 36.2%
- Operating margin
- -51.5%
- Net margin
- -48.1%
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $4.9M
- Cost of revenue
- $3.1M
- Gross profit
- $1.8M
- Operating expenses
- $4.3M
- Operating income
- -$2.5M
- Income tax
- $8.0K
- Net income
- -$2.3M
- EPS (basic)
- $-1.71
- EPS (diluted)
- $-1.71
Balance sheet
- Total assets
- $6.5M
- Current assets
- $6.4M
- Total liabilities
- $2.4M
- Current liabilities
- $2.1M
- Shareholders’ equity
- $4.1M
Cash flow
- Operating cash flow
- -$4.7M
- Investing cash flow
- $750.0K
- Financing cash flow
- $6.0K
- Net cash flow
- -$4.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $2.2M
- EPS (diluted)
- $-1.71
- Shares outstanding
- 3.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 15, 2015
At a glance
- Reported a net loss of $2.3M in FY2025.
- Revenue declined 28% from FY2021 to FY2025.
- Gross margin of 36.2%, net margin -48.1%.
- Trading 88% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Arcadia Biosciences, Inc..
Write a review
News about Arcadia Biosciences, Inc.
News & sentiment via Polygon.io
